| Village Podiatry Group, L.l.c. | |
|
1350 Upper Hembree Rd Ste 100, Roswell, GA 30076-0929 | |
| (678) 426-2171 | |
| (404) 446-1957 |
| Full Name | Village Podiatry Group, L.l.c. |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 1350 Upper Hembree Rd Ste 100, Roswell, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508846718 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | (* (Not Available)) | Primary |
| Provider Name | Mitchell P Hilsen |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1558327809 PECOS PAC ID: 0143297473 Enrollment ID: I20040915000499 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Stuart M Tuck |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1649230335 PECOS PAC ID: 8224082599 Enrollment ID: I20050309000664 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Craig A Camasta |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1235131079 PECOS PAC ID: 5799674081 Enrollment ID: I20050404001114 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Jennifer S Price |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1124010863 PECOS PAC ID: 4981641651 Enrollment ID: I20050413001299 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Stephanie Michael |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1790775559 PECOS PAC ID: 6800837022 Enrollment ID: I20050518000797 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Mark M Snyder |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1801859053 PECOS PAC ID: 7911949136 Enrollment ID: I20050527000495 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Clair Bello |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1518960855 PECOS PAC ID: 3971594250 Enrollment ID: I20050609000798 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | La Genia D.p.m. Mitchell Smith |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1467444570 PECOS PAC ID: 3476581950 Enrollment ID: I20050727000639 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Michael Miller |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1104816941 PECOS PAC ID: 3971514118 Enrollment ID: I20060601000028 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Allen T Raphael |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1770539801 PECOS PAC ID: 7113930975 Enrollment ID: I20060720000259 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Dane A Ulett |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1992767594 PECOS PAC ID: 1759394430 Enrollment ID: I20060725000103 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | John A Ruch |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1548282551 PECOS PAC ID: 6608979760 Enrollment ID: I20070320000422 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Alan S Banks |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1639191646 PECOS PAC ID: 3971606039 Enrollment ID: I20070320000426 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Lawanna K Monday |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1568663144 PECOS PAC ID: 7911008396 Enrollment ID: I20070730000427 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Steven A Weiskopf |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1750388237 PECOS PAC ID: 0345272563 Enrollment ID: I20080626000238 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Pinecca Patel Raval |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1003012949 PECOS PAC ID: 3476625070 Enrollment ID: I20080626000265 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Andrew D Warner |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1518927292 PECOS PAC ID: 3072569870 Enrollment ID: I20080626000463 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Anthony M Cutsuries |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1124093273 PECOS PAC ID: 9032157037 Enrollment ID: I20080716000341 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Richard C Aronoff |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1346202942 PECOS PAC ID: 8527132463 Enrollment ID: I20080811000419 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | David A Bell |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1881795599 PECOS PAC ID: 7416917836 Enrollment ID: I20090831000362 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Mohammad A Sharif |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1851357164 PECOS PAC ID: 0345343406 Enrollment ID: I20100209000546 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Rudolph Cisco |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1043236706 PECOS PAC ID: 1557406592 Enrollment ID: I20100302000881 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Aaron Solomon |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1356344691 PECOS PAC ID: 3678577715 Enrollment ID: I20100913000034 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Zia Mustafa |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1972826576 PECOS PAC ID: 6800084971 Enrollment ID: I20121024000615 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Sadia Ali |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1467614438 PECOS PAC ID: 3577731959 Enrollment ID: I20130515000520 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Christopher Russel Corwin |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1003850983 PECOS PAC ID: 0547272155 Enrollment ID: I20130620000309 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Cheree Shantell Eldridge |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1891059887 PECOS PAC ID: 5597072017 Enrollment ID: I20150916001547 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Vann Johnson |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1902108053 PECOS PAC ID: 7012187727 Enrollment ID: I20151221001478 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Sam Bazrafshan |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1417314477 PECOS PAC ID: 4880989656 Enrollment ID: I20160923001705 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Sneha Suthar |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1659781482 PECOS PAC ID: 6709165822 Enrollment ID: I20161114001074 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Shelley May Brand |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1154702827 PECOS PAC ID: 0941551360 Enrollment ID: I20180925001514 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | David Q Anderson |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1780683136 PECOS PAC ID: 8224237649 Enrollment ID: I20190226002502 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Monica S. Dontamsetti |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1922459759 PECOS PAC ID: 6204171275 Enrollment ID: I20190814003088 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Rizcion Bamba Dagani |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1801291950 PECOS PAC ID: 0941633374 Enrollment ID: I20191125003199 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Errol Scarlett |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1427548346 PECOS PAC ID: 6800144395 Enrollment ID: I20210623000158 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Gurleen Kaur Brar |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1154818235 PECOS PAC ID: 8022411412 Enrollment ID: I20210722002152 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Amy G. Wilson |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1033606967 PECOS PAC ID: 5294126900 Enrollment ID: I20220106000767 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | John C. Haight |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1154941714 PECOS PAC ID: 9032540281 Enrollment ID: I20220325000173 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | John A. Martucci |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1083111207 PECOS PAC ID: 8729488143 Enrollment ID: I20220720002512 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Samantha A Miner |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1932604170 PECOS PAC ID: 0840549366 Enrollment ID: I20220728002802 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Navita Khatri |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1205457348 PECOS PAC ID: 9537541727 Enrollment ID: I20220804001924 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Khatija Sultana Ahmed |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1467017038 PECOS PAC ID: 0042692998 Enrollment ID: I20220809002255 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Kelly A. Mckeon |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1184243305 PECOS PAC ID: 3577921857 Enrollment ID: I20230619000677 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Zaheer Ahammad |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1205491065 PECOS PAC ID: 1254799406 Enrollment ID: I20230620001716 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Trey M. Edwards |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1245868405 PECOS PAC ID: 8527426634 Enrollment ID: I20230622001105 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Guang Yang |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1417417742 PECOS PAC ID: 5597123265 Enrollment ID: I20230628001405 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Provider Name | Marina Romany Tony |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1932726809 PECOS PAC ID: 5294158978 Enrollment ID: I20230712002747 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Village Podiatry Group, L.l.c. 1350 Upper Hembree Rd Ste 100, Roswell, GA 30076-0929 Ph: (678) 426-2171 | Village Podiatry Group, L.l.c. 1350 Upper Hembree Rd Ste 100, Roswell, GA 30076-0929 Ph: (678) 426-2171 |
News Archive
Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.
Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.
Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.
e-MDs, an industry leader in the development and implementation of electronic health record (EHR) and practice management (PM) solutions, announced they have been named a selected EHR vendor and Implementation Optimization Organization (IOO) by the Massachusetts eHealth Institute (MeHI). The Institute will serve as a Regional Extension Center (REC) in Massachusetts, working to facilitate the adoption of EHR technology by the state's providers. As a selected vendor, e-MDs will help ensure effective implementation and provider achievement of Meaningful Use.
› Verified 4 days ago
Serenity Podiatry And Med Spa Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 770 Old Roswell Pl Ste A300, Roswell, GA 30076 Phone: 347-281-2620 | |
Village Podiatry Group, Llc. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1350 Upper Hembree Rd Ste 100, Roswell, GA 30076 Phone: 678-426-2171 Fax: 404-446-1957 | |
Dr. Richard Kaufman, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 990 Holcomb Bridge Rd Ste 4, Roswell, GA 30076 Phone: 770-992-9980 Fax: 770-641-0378 | |
Dr. Sarepta Isaac, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 770 Old Roswell Pl Ste A300, Roswell, GA 30076 Phone: 678-373-3050 | |
Dr. Dean P Kostakos, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1380 Upper Hembree Rd, Roswell, GA 30076 Phone: 770-346-7500 Fax: 770-346-8800 | |
Ehi Clinical Study Research Center, Llc. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1357 Hembree Rd Ste 101, Roswell, GA 30076 Phone: 770-280-2406 |